The DEpth of Endoscopic Perforation scale to assess intraoperative perforations during transurethral resection of bladder tumor: subgroup analysis of a randomized controlled trial.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 19 04 2022
accepted: 02 05 2022
medline: 23 10 2023
pubmed: 7 6 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

Bladder perforation (BP) is the most important intraoperative adverse event of transurethral resection of bladder tumor (TURBT). It is frequently underreported despite its impact on the postoperative course. There is no standardized classification of BP. The study aims to develop a classification of the depth of endoscopic bladder perforation during TURBT. This is a sub-analysis of a prospective randomized trial enrolling 248 patients submitted to en-bloc vs conventional TURBT from 03/2018 to 06/2021. The DEpth of Endoscopic Perforation (DEEP) scale is as follows: "0" visible muscular layer with no perivesical fat; "1" visible muscle fibers with spotted perivesical fat; "2" exposition of perivesical fat; "3" intraperitoneal perforation. Logistic and linear regression models were used to investigate predictors of high-grade perforations (DEEP 2-3) and to assess whether the DEEP scale independently predicted patients' postoperative outcomes. A total of 146/248 (58.9%), 56/248 (22.6%), 41/248 (16.5%), 5/248 (2.0%) patients presented DEEP grade 0, 1, 2, and 3, respectively. Female gender [B coeff. 0.255 (95% CI 0.001-0.513); p = 0.05], tumor location [B coeff. 0.188 (0.026-0.339); p = 0.015], and obturator-nerve reflex [B coeff. 0.503 (0.148-0.857); p = 0.006] were independent predictors of DEEP. The scale predicted independently major complications [Odd Ratio (OR) 2.221 (1.098-4.495); p = 0.026], no post-operative chemotherapy intravesical instillation [OR 9.387 (2.434-36.200); p = 0.001], longer irrigation time [B coeff. 0.299 (0.166-0.441); p < 0.001] and hospital stay [B coeff. 0.315 (0.111-0.519); p = 0.003]. The DEEP scale provides a visual tool for grading bladder perforation during TURBT, which can help physicians standardize complication reporting and plan postoperative management accordingly.

Identifiants

pubmed: 35665840
doi: 10.1007/s00345-022-04052-w
pii: 10.1007/s00345-022-04052-w
pmc: PMC9166183
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2583-2589

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81:75–94. https://doi.org/10.1016/j.eururo.2021.08.010
doi: 10.1016/j.eururo.2021.08.010 pubmed: 34511303
Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M et al (2019) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol 30:1697–1727. https://doi.org/10.1093/annonc/mdz296
doi: 10.1093/annonc/mdz296 pubmed: 31740927
Cornu JN, Herrmann T, Traxer O, Matlaga B (2016) Prevention and management following complications from endourology procedures. Eur Urol Focus 2:49–59. https://doi.org/10.1016/j.euf.2016.03.014
doi: 10.1016/j.euf.2016.03.014 pubmed: 28723449
Akand M, Muilwijk T, Raskin Y, De Vrieze M, Joniau S, Van Der Aa F (2019) Quality control indicators for transurethral resection of non-muscle-invasive bladder cancer. Clin Genitourin Cancer 17:e784–e792. https://doi.org/10.1016/j.clgc.2019.04.014
doi: 10.1016/j.clgc.2019.04.014 pubmed: 31097388
Traxer O, Pasqui F, Gattegno B, Pearle MS (2004) Technique and complications of transurethral surgery for bladder tumours. BJU Int 94:492–496. https://doi.org/10.1111/j.1464-410X.2004.04990.x
doi: 10.1111/j.1464-410X.2004.04990.x pubmed: 15329099
Lonati C, Esperto F, Scarpa RM, Papalia R, Gómez Rivas J, Alvarez-Maestro M et al (2021) Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow up. Minerva Urol Nephrol. https://doi.org/10.23736/S2724-6051.21.04436-0
doi: 10.23736/S2724-6051.21.04436-0 pubmed: 34263743
Biyani CS, Pecanka J, Rouprêt M, Jensen JB, Mitropoulos D (2020) Intraoperative Adverse Incident Classification (EAUiaiC) by the European association of urology ad hoc complications guidelines panel. Eur Urol 77:601–610. https://doi.org/10.1016/j.eururo.2019.11.015
doi: 10.1016/j.eururo.2019.11.015 pubmed: 31787430
Cacciamani G, Sholklapper T, Sotelo R, Desai M, Gill I (2021) A protocol for the development of the intraoperative complications assessment and reporting with universal standards criteria: the ICARUS project. Int J Surg Protoc 25:160–164. https://doi.org/10.29337/ijsp.155
doi: 10.29337/ijsp.155 pubmed: 34430764 pmcid: 8344953
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae pubmed: 15273542 pmcid: 1360123
Collado A, Chéchile GE, Salvador J, Vicente J (2000) Early complications of endoscopic treatment for superficial bladder tumors. J Urol 164:1529–1532
doi: 10.1016/S0022-5347(05)67021-8 pubmed: 11025697
Comploj E, Dechet CB, Mian M, Trenti E, Palermo S, Lodde M et al (2014) Perforation during TUR of bladder tumours influences the natural history of superficial bladder cancer. World J Urol 32:1219–1223. https://doi.org/10.1007/s00345-013-1197-x
doi: 10.1007/s00345-013-1197-x pubmed: 24166290
Ohguchi N, Sakaida N, Okamura A, Kawakita S, Kawamura H, Matsuda T (1997) Extravesical tumor implantation caused by perforation during transurethral resection of a bladder tumor: a case report. Int J Urol 4:516–518. https://doi.org/10.1111/j.1442-2042.1997.tb00296.x
doi: 10.1111/j.1442-2042.1997.tb00296.x pubmed: 9354957
Kim JH, Yang WJ (2014) Delayed spontaneous perforation of urinary bladder with intraperitoneal seeding following radical transurethral resection of invasive urothelial cancer: a case report. BMC Res Notes 7:167. https://doi.org/10.1186/1756-0500-7-167
doi: 10.1186/1756-0500-7-167 pubmed: 24650321 pmcid: 3994548
Skolarikos A, Chrisofos M, Ferakis N, Papatsoris A, Dellis A, Deliveliotis C (2005) Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence? J Urol 173:1908–1911. https://doi.org/10.1097/01.ju.0000158450.71497.ae
doi: 10.1097/01.ju.0000158450.71497.ae pubmed: 15879773

Auteurs

Alberto Breda (A)

Department of Urology, Fundació Puigvert, Barcelona, Spain. albbred@hotmail.com.
Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain. albbred@hotmail.com.

Andrea Gallioli (A)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Pietro Diana (P)

Department of Urology, Fundació Puigvert, Barcelona, Spain.
Department of Urology, Humanitas Research Hospital-IRCCS, Rozzano, Italy.

Matteo Fontana (M)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Angelo Territo (A)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Josep Maria Gaya (JM)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Óscar Rodriguez-Faba (Ó)

Department of Urology, Fundació Puigvert, Barcelona, Spain.
Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain.

Jordi Huguet (J)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Alberto Piana (A)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Paolo Verri (P)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Michael Baboudjian (M)

Department of Urology, Fundació Puigvert, Barcelona, Spain.
Department of Urology, North Hospital, APHM, Marseille, France.

Julia Aumatell (J)

Department of Urology, Fundació Puigvert, Barcelona, Spain.

Ferran Algaba (F)

Fundació Puigvert, Department of Pathology, Autonomous University of Barcelona, Barcelona, Spain.

Joan Palou (J)

Department of Urology, Fundació Puigvert, Barcelona, Spain.
Department of Surgery, Autonomous University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH